Efficacy and safety of fluticasone furoate/vilanterol or tiotropium in subjects with COPD at cardiovascular risk

BACKGROUND: Fluticasone furoate/vilanterol (FF/VI) is a novel, once-daily, inhaled corticosteroid/long-acting β(2)-agonist combination approved for the treatment of COPD and asthma. We compared the safety and efficacy of FF/VI and tiotropium (TIO) in subjects with moderate-to-severe COPD with greate...

Descripción completa

Detalles Bibliográficos
Autores principales: Covelli, Henry, Pek, Bonavuth, Schenkenberger, Isabelle, Scott-Wilson, Catherine, Emmett, Amanda, Crim, Courtney
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2015
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4694692/
https://www.ncbi.nlm.nih.gov/pubmed/26730183
http://dx.doi.org/10.2147/COPD.S91407

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4694692/
https://www.ncbi.nlm.nih.gov/pubmed/26730183
http://dx.doi.org/10.2147/COPD.S91407

Ejemplares similares